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Chapter 5
Integrin v3 as a target in the prevention of
neointimal hyperplasia
Taku Kokubo, MD,a Hisashi Uchida, MD,a and Eric T. Choi, MD,a,b St. Louis, Mo
Although major advances have been made in the prevention and treatment of restenosis following coronary and peripheral
interventions, the persistent complications of thrombosis and reintervention remain a mainstay for repeat hospitalizations in
this patient population. For many years, a ubiquitous cell surface receptor called v3 integrin was the target of investigators
in the prevention of restenosis because its interaction with the extracellular matrix was believed to coordinate the migration of
smoothmuscle cells (SMCs) from themedia to the intima, the seminal event in the formation of intimal occlusive lesion. After
the publication of uniformly positive animal studies demonstrating that v3 integrin blockade led to a significant reduction
in new intimal (neointimal) lesion formation, early clinical trials supported the association of avoidance of target lesion
revascularization and the use of antagonists to the SMC integrinv3 and its related platelet integrinIIb3.However, a series
of clinical trials subsequently demonstrated that these antagonists did not necessarily prevent revascularizations by inhibiting
intimal hyperplasia per se. Additional animal studies subsequently showed that, indeed, in the setting of pre-existing SMCs in
the intimal lesion (ie, atherosclerotic plaque, fatty streaks), inhibiting SMCmigration by way of 3 integrin blockade was an
ineffective approach in the prevention of intimal hyperplasia and restenosis. However, given the wealth of basic and clinical
information on the v3 integrin and its antagonists, we discuss in this article our new approach to this old solution by
targeting a new clinical problem of early failure arteriovenous access for hemodialysis. Given the uniqueness of arteriovenous
access in that there are essentially no significant atherosclerotic lesions in the artery and vein prior to the anastomosis, the
seminal event of the migration of SMCs from the media to the neointima could by targeted once again with  integrin3
antagonists. (J Vasc Surg 2007;45:33A-38A.)Although significant advances have been made in the
primary (eg, surgical bypass, angioplasty, and stenting) and
secondary treatments (eg, drug-eluting stents) for coronary
and peripheral arterial occlusive disease, the ultimate solu-
tion to the persistent problems of anastomotic and in-stent
arterial narrowing and thrombosis remains elusive.1,2 The
pathology of arterial restenosis is thought to be multifac-
toral with a number of specific biochemical and cellular
events.3,4
The initial response to the arterial wall via the anasto-
mosis or the overstretching by balloon catheter is elastic
recoil (constrictive remodeling), which characterizes the
early and late phases of restenosis. Endothelial disruption
and exposure of subintimal components initiate the middle
phase with platelet adherence and aggregation, fibrinogen
binding, and thrombus formation. In turn, the thrombus
creates a scaffold into which smooth muscle cells (SMCs)
can migrate and provide the substrates for intimal growth
or intimal hyperplasia. Moreover, inflammatory mediators
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doi:10.1016/j.jvs.2007.02.069and cellular elements contribute to trigger a complex array
of events that modulate matrix production and intimal
cellular proliferation. This article focuses on the v3 inte-
grin, a cell surface receptor, as a potential therapeutic target
for the prevention of SMC migration and restenosis.
STRUCTURE, FUNCTION, AND
DISTRIBUTION OF v3 INTEGRIN
Integrins are a family of transmembrane glycoproteins
that mediate cell– cell and cell–matrix interaction.5 All
known members of this superfamily are noncovalently as-
sociated heterodimers composed of an  and a  subunit.
At present, at least 8  and 18  subunits have been
characterized, and these subunits associate to generate at
least 24 different integrins.5 For instance, subunit 3 asso-
ciates with subunits IIb and v to generate integrins IIb3
and v3. Integrins are type I membrane proteins with a
large extracellular, a transmembrane and a short cytoplas-
mic domains. The interaction between integrins and their
ligands, besides mediating cell adhesion, is important in a
number of cellular processes.6
One of the most prevalent integrins, v3 is expressed
on almost all the cells originating from the mesenchyme
and on a variety of cell types in the blood vessel, including
endothelial cells, SMCs, fibroblasts, macrophage, and
platelets. It is known to mediate many biologic events such
as migration of vascular SMCs, adhesion of osteoclasts to
the bone matrix, and angiogenesis. It is the most promis-
cuous integrin, for it binds to many different ligands and a
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tin, fibronectin, osteopontin, fibrinogen, and von Wille-
brand factor, by the interaction with the Arg-Gly-Asp
(RGD) motif.5,7 Conversely, a related integrin, IIb3 is
exclusively expressed on platelets and is largely responsible
for the final cohesive phase of platelet activation in vivo,
such as platelet aggregation supported by the binding of
adhesive protein.8 Of interest is that the Vb3 integrin
recognize the same RGD motif and binds to the same
extracellular matrix proteins.9,10
Osteopontin one of the ligands for v3, contains the
canonical integrin recognition sequence, RGD, and binds to
v3 integrin through the sequence.
11 In vitro studies have
demonstrated that osteopontin promotes the migration of
cultured rat arterial SMCs12 and human coronary artery
SMCs.13 Previous data showed that osteopontin was coordi-
nately expressed with 3 integrins in the vessel wall and that a
blockade of v3 resulted in a reduction of neointimal forma-
tion in animal models after vascular injury.14 These data
suggest that v3 binding to osteopontin is important in
mediating SMCmigration from themedia to the neointima in
vivo.
The integrin-mediated adhesion of cells to extracellular
matrix leads bidirectional intracellular signaling events that
regulate cell migration, survival, and proliferation. In out-
side-in signaling, ligand binding activates intracellular sig-
naling pathways. In inside-out signaling, signals received by
other receptors activate intracellular signaling pathways
that impinge on integrin cytoplasmic domains and change
the extracellular domain conformation for binding to li-
gands.5
Recent studies have shown that v3 expression on
SMCs is subject to regulation and is increased by treatment
with thrombin,15 transforming growth factor- (TGF-),
and platelet-derived growth factor-BB (PDGF-BB).16 In
endothelial cells, vascular endothelial growth factor
(VEGF) can induce activation of v3 and nuclear factor-
B3 (NF-B3), which leads to suppression of p53 and
p21WAF1/CIP1.17,18 Moreover v3, along with mem-
brane type 1 (MT1) matrix metalloproteinase-1 (MMP-1),
is associated with MMP-2 at the cell surface.19,20
The MMPs belong to a family of zinc-dependent en-
dopeptidases that degrade many components of the extra-
cellular matrix. Most MMPs are secreted in a latent form
(pro-MMP), and a specific multistep activation process is
required to convert pro-MMP to proteolytic active forms.
Localization of functionally active MMP on the cell surface
is an essential and tightly regulated element during a variety
of normal and disease processes, such as tumor cell inva-
sion.21 For instance, MMP-2 is activated at the cell surface
of invasive cells by a multimeric receptor/activation com-
plex consisting of the tissue inhibitor of metalloproteinase 2
(TIMP2), and MT1-MMP.22
In line with the theory of cellular invasion requiring a
coordinated expression of proteolytic enzymes and adhe-
sion molecules, Hofmann et al23 suggested that functional
cooperation of MT1-MMP and v3 is critical for spatial
and temporal control of extracellular matrix proteolysis inhuman melanoma cells. They indicated that joint MT1-
MMP and v3 might enforce the most efficient docking
and activation of MMP-2, and in turn, facilitate cellular
locomotion. Furthermore, Brooks et al19 demonstrated
that the functionally active form of MMP-2 on the cell
surface seems to predominantly involve v3 in angiogen-
esis and concomitant melanoma growth.
v3 INTEGRIN AND ANIMAL MODELS OF
ARTERIAL INJURY
Our group first reported the potential therapeutic ben-
efit of v3 blockade in the prevention of intimal hyperpla-
sia and restenosis.24 We demonstrated that PDGF, a potent
chemotactic agent present in the arterial wall after injury,
regulates the surface distribution of v3 on the SMC
surface in cell culture. Using indirect immunofluorescence,
focal adhesions containing v3 were localized to the lead-
ing edge of migrating cells when stimulated with PDGF. In
contrast, v3 was evenly distributed on the surface of
SMCs grown in the absence of PDGF. These results sug-
gest that a redistribution of v3 in focal adhesion is
necessary for SMC motility.
In an in vitro assay, we determined that PDGF-induced
human SMCmigration is mediated by v3 by using a block-
ing antibody to v3 (LM609). This PDGF-mediatedmigra-
tion was also attenuated with a v3-blocking RGD peptide
(GpenGRGDSPCA), demonstrating that the RGD sequence
is the binding site in the extracellular matrix proteins.
We also tested the effects of the local administration of
this RGD peptide in a rabbit model of carotid balloon
angioplasty injury. This RGD antagonist was delivered to
the adventitia of the injured artery and inhibited the new
intimal (neointimal) lesion formation by 70%. Neointimal
hyperplasia seen in an animal model should be distin-
guished from intimal hyperplasia seen in humans because
there are no inherent SMCs in the noninjured intimal layer
in most, normocholesterolemic animals. The same peptide
locally applied to the carotid artery through an adventitial
Pluronic gel (Sigma-Aldrich, Inc., St. Louis, Mo) in rats led
to a 92% reduction in neointimal hyperplasia after a similar
balloon angioplasty injury.25
In humans, v3 is present both in normal artery and in
sites of SMC accumulation and angiogenesis in atheroscle-
rotic plaques.26 It is generally detectable in normal artery
only along the luminal surface, with minimal expression in
the media.26,27 Several studies in animal models have
shown that arterial injury is a stimulus for expression of
v3 by endothelial cells and medial SMCs.
24,27 For in-
stance, Srivatsa et al28 showed in the pig coronary stent
model that an upregulation of v3 takes place at sites of
cell accumulation within the neointima and adventitia at 7
days after arterial injury, followed by persistent high levels
of v3 expression within the media and neointima up to
21 days, decreasing towards baseline by 28 days. Indeed,
Table I29-35 summarizes a number of reports demonstrat-
ing the efficacy of v3 and IIb3 antagonists in the
reduction of neointimal hyperplasia in a variety of species.
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The results from the animal studies were consistent
with findings from the early clinical trials examining the
effect of various antagonists to platelet integrin IIb3 and
SMC integrin v3 on the issue of long-term benefit of
reduced target lesion revascularization (Table II).36-40 In
the Evaluation of Platelet IIb/IIIa Inhibition for Preven-
tion of Ischemic Complications (EPIC) trial, ReoPro (ab-
ciximab, anmonoclonal antibody fragment directed against
the 3 integrin; Centocor, Inc, Horsham, Pa) was effective
in limiting the need for late revascularization after angio-
plasty for at least 3 years after treatment.41 A subsequent
study confirmed that ReoPro treatment reduced ischemic
complications and late mortality, particularly in the diabetic
population.37
In the Integrilin to Minimize Platelet Aggregation and
Coronary Thrombosis (IMPACT) II trial, however, Inte-
grilin (an agent with anti-IIb3 activity but without spe-
cific v3 inhibitory activity; Millennium Pharmaceuticals,
Cambridge, Mass) was ineffective in reducing coronary
revascularizations in the same clinical setting as the EPIC
trial.38 As in the animal studies, these clinical results suggest
that IIb3 integrin inhibition had no place in the treat-
ment of coronary restenosis. However, a more detailed
clinical study, the Evaluation of ReoPro And Stenting to
Eliminate Restenosis (ERASER) trial, revealed that ReoPro
Table I. Scientific investigations on the effectiveness of th
formation in various animal models of arterial injury
Species (ref) Antagonist 3 integrin
Rat25,29 ReoPr v3, IIb3
Rat30 Gpen v3
Hamster31 Gpen v3
Hamster32 FK633 IIb3
Rabbit24 Gpen v3
Rabbit33 Vitaxi v3
Rabbit34 AZ-1 IIb3
Pig28 XJ 735 v3
Monkey35 ReoPro v3, IIb3
Monkey35 ReoPro v3, IIb3
IH, Intimal hyperplastic.
Table II. Clinical trials on the effectiveness of the 3 integ
arteries
Study (ref) Antagonist 3 integrin
EPIC36 ReoPro v3, IIb
Lincoff et al37 ReoPro v3, IIb
IMPACT II38 Integrilin IIb3
ERASER39 ReoPro v3, IIb
CAPTURE40 ReoPro v3, IIb
TLR, Targeted lesion revascularization; EPIC, Evaluation of Platelet IIb/I
Minimize Platelet Aggregation and Coronary Thrombosis; ERASER, Eval
Antiplatelet Therapy in Unstable Refractory Angina.given at the time of or a short duration after coronaryangioplasty and stenting had little or no effect on the size of
the intimal hyperplastic lesion as measured by intravascular
ultrasound.39
Still, these clinical trials did not adequately address the
role of v3 in restenosis because short-term infusions of
Integrilin and ReoPro would not be expected to block v3
during crucial periods of vascular repair. Bleeding compli-
cations limited the long-term administration of these an-
tagonists during percutaneous intervention to humans.
Indeed, there is no certainty the local concentrations of
these antagonists in the vessel wall are sufficient to inhibit
v3 integrin clinically.
v3 INTEGRIN AND THE CLINICAL
SIGNIFICANCE BASED ON ANIMAL MODELS
Because the exact role of v3 in intimal hyperplastic
lesion formation and restenosis remains unknown, it be-
came critical to re-examine the precise mechanism of action
of v3 in cell culture and in animal models. Indeed, Azrin
et al34 tested in a hypercholesterolemic rabbit model of
balloon angioplasty with pre-existing atherosclerotic le-
sions an antibody (AZ-1) that binds to the rabbit platelet
IIb3 and inhibits platelet function in vivo. No significant
differences were found in intimal hyperplastic lesion forma-
tion between the AZ-1 antibody-treated and control
groups 4 weeks after angioplasty. In this case, the IIb3
antagonist failed to inhibit restenosis in the setting of
integrin antagonists in the inhibition of intimal lesion
Artery Injury type IH lesion reduction?
arotid Angioplasty Yes
arotid Angioplasty Yes
arotid Angioplasty Yes
arotid Angioplasty Yes
arotid Angioplasty Yes
arotid Angioplasty Yes
emoral Angioplasty No
oronary Stenting Yes
liac Angioplasty No
ubclavian Stenting No
ntagonists in the inhibition of restenosis in the coronary
Injury type TLR
Angioplasty, atherectomy Reduced
Stenting Reduced
Angioplasty No difference
Stenting No difference
Angioplasty No difference
hibition for Prevention of Ischemic Complications; IMPACT, Integrilin to
of ReoPro And Stenting to Eliminate Restenosis; CAPTURE, C7E3 Fabe 3
C
C
C
C
C
C
F
C
I
Srin a
3
3
3
3
IIa In
uationpre-existing intimal lesion, similar to the human clinical
JOURNAL OF VASCULAR SURGERY
June Supplement 200736A Kokubo, Uchida, and Choisituation where SMCmigration is not a requisite for intimal
lesion generation.
Although the case could be made only against the
IIb3 antagonists in the treatment of intimal hyperplasia,
Deitch et al35 reported that ReoPro failed to reduce intimal
hyperplastic lesion formation in atherosclerotic nonhuman
primates after angioplasty and stenting in separate arteries,
suggesting that blockade of SMCmigration is not critical in
the setting of pre-existing intimal SMCs.
Since the publication of the reports on the ineffective-
ness of v3 blockade on the intimal hyperplasia develop-
ment in complex animal models, Smyth et al42 used a
combination of guidewire-induced endothelial denudation
and arterial ligation to demonstrate that 3-integrin defi-
ciency (3
–/–) did not have a role in intimal lesion forma-
tion. Our group, however, later classified the injury meth-
odology by creating three distinct injury patterns that
differed in the extent of medial injury induced in these
3
–/– mice: (1) guidewire probe–induced transmural injury
with medial disruption, (2) nonmedial disruptive ligation
injury, and (3) eccentric medial disruptive injury, followed
by arterial ligation.43 We believed that injury induced by
guidewire probe generated more transmural mechanical
damage to the media over a longer segment of the vessel
compared with the ligation injury, which generates a more
modest, focal lesion with stagnant flow and thrombosis.
As before, we showed that 3-integrin deficiency did
not protect against neointimal lesion formation after a
significant medial disruption seen with guidewire probe
injury. In contrast, in the setting of arterial ligation injury,
3-integrin deficiency protected against neointimal lesion
formation at 1, 2, and 3 weeks, and 3 months after injury.
When the combination of medial disruption and arterial
ligation was used in 3
–/– mice, eccentric neointimal lesion
formation occurred only at the site of disruption. The lack
of neointimal lesion formation on the opposite, nondis-
rupted section is consistent with the dependence of neoin-
timal formation on the mechanical disruption of the inter-
nal elastic lamina and media as described by others.44
One satisfactory explanation for only discrepancies
from the arterial injury patterns in 3
–/– mice is that differ-
ent models or methodologies accentuate the various, dis-
tinct functions of 3 integrins. For instance, Carmeliet et
al45 compared intima formation induced by mechanical
injury in mice deficient in plasminogen activator inhibitor 1
(PAI-1) and in wild-type mice and demonstrated that
PAI-1 blocks intimal thickening by inhibiting the migra-
tion of SMCs. In contrast, Peng et al46 demonstrated that
when ligation-induced intima formation was examined in
PAI-1/ and PAI-1–/– mice, PAI-1 promoted neointimal
thickening. One can conclude that these injury models
emphasize a contrasting cascade of events despite the ap-
parently simple injuries.
Moreover, Tanaka et al47 showed in a carotid ligation
injury model that there is minimal bone marrow–derived
cell contribution to the neointimal lesion development.
Therefore, in the carotid ligation model of intimal hyper-
plasia, the seminal event appears to be a directional cellularmigration from the media to the neointima with the aid of
v3, with little or no contribution from the bone marrow
(Fig, B). Hence, although 3-integrin blockade effectively
reduces neointimal hyperplasia in animal models, this
blockade may not be effective for prevention of neointimal
lesion formation in the less defined, more disruptive injury
induced by percutaneous transluminal coronary angio-
plasty in human coronary arteries (Fig, A).
FUTURE DIRECTIONS
Complications with hemodialysis access constitute a
major cause of morbidity for patients with end-stage kidney
disease. In the United States alone, expanded polytetra-
fluoroethylene (ePTFE) grafts are used for permanent vas-
cular access in approximately 70% of the 250,000 patients
receiving hemodialysis.48 Currently, the primary patency
rates of these ePTFE grafts at 1 and 2 years are 50% and
25%, respectively, while hospitalizations related to hemo-
dialysis access cost well over $1 billion dollars per annum.49
The failure of hemodialysis access grafts is predomi-
nantly due to a neointimal hyperplastic response in the
region of the venous anastomosis resulting in reduction of
shunt flow and ineffective hemodialysis. The access then
needs to be revised by an open surgical revision or a
percutaneous angioplasty or stenting, or both. By then,
placement of another hemodialysis access at a difference site
is not far off, quickly exhausting the available sites predom-
inantly in the upper extremities.
Castier et al50 recently created an arteriovenous fistula
Fig. Leading animal models of arterial injury. A, The balloon
angioplasty model results in a disruptive injury to the intima and
media leading to neointimal hyperplastic lesion formation with a
significant smooth muscle cell (SMC) contribution from the bone
marrow. B, The carotid ligation (flow cessation) model results in
little or no disruptive injury to the media. The seminal event
appears to be a directional SMC migration from the media to the
neointima with little or no contribution from the bone marrow.C,
Like the carotid ligation model, the critical event appears to be
SMC migration with minimal or no medial disruption and bone
marrow contribution.model in mice that demonstrated a rapid neointimal hyper-
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vant to the clinical problem of venous neointimal hyperpla-
sia and acute thrombosis. This arteriovenous fistula model
results in traumatic injury to the blood vessels involved and
turbulent blood flow near the anastomosis, along with a
compliance mismatch between artery and vein, which are
believed to be factors that produce the rapid neointimal
lesion formation. They further demonstrated that like the
arterial ligation injury model, the neointimal SMCs of the
arteriovenous fistula anastomosis do not originate from
bone marrow stem cells. Hence, they have demonstrated
that this animal model and the clinical situation of arterio-
venous access surgery for hemodialysis are uniquely suited
to target the seminal event in the formation of the neoin-
timal lesion formation, the SMC migration (Fig, C).
Unlike intimal hyperplasia seen with preocclusive
atherosclerotic arteries after angioplasty and stenting,
neointimal hyperplasia is seen with an anastomosis in-
volving a synthetic graft (eg, ePTFE, Dacron) and a
relatively disease-free segment of vein or artery. There is
thus no preprocedural, stenotic intimal plaque with
abundant resident SMCs, and therefore, adhesion and
directional migration (relocation) of SMCs into the pro-
visional matrix on the luminal surface are indeed the
seminal events, not unlike the invasive tumor cells (me-
tastasis).
In this setting of end-stage kidney disease and arterio-
venous access, targeting v3 integrin could have a signif-
icant impact on the prevention of neointimal hyperplasia.
Indeed, animal studies examining the role of the v3
antagonists on the long-term patency of the arteriovenous
accesses need to be performed in the setting of uremia, and
then perhaps properly designed clinical trials in this patient
population with kidney disease might ultimately provide a
clinical problem to this old solution.
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